Gilde Healthcare IV, which closed at its hard cap, is backed by a mix of international investors including Royal Philips and Johnson & Johnson. Additional investors include fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners. The European Investment Fund participated in the fund through several of its funding programs including the European Recovery Program and Dutch Venture Initiative II.
In the last three years, Gilde exited 14 portfolio companies across its healthcare funds realizing significant value for its investors. Amongst the companies that were successfully divested over this period are Definiens, a provider of image analysis software for digital pathology; Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions; ProFibrix, which developed a novel topical hemostatic agent to treat fast bleeding wounds; Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design; Santaris, which develops RNA-targeted drugs; and Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson's disease.
"The healthcare landscape in the U.S. and Europe is changing, driven by the need for more patient centric care and a much sharper focus on value. With our new fund we will continue to pursue our differentiated investment strategy of backing growth and later stage companies developing novel technologies or therapeutics that enable better healthcare outcomes at reduced costs," said Pieter van der Meer, managing partner of Gilde Healthcare.
The Gilde Healthcare IV Fund will make equity investments in a single portfolio company of between 15 million and 25 million euros.
Gilde Healthcare is based in Utrecht, The Netherlands, and Cambridge, Mass. The firm is organized along two business lines managing separate funds for innovative healthcare technology companies and lower mid-market healthcare services companies. Gilde has raised more than 800 million euros ($910 million) in dedicated healthcare funds and is actively looking to lead new private investments in medtech, digital health, therapeutics and healthcare services.